Updated: 18/12/2025 | Read time: 2 min
Making waves with Crux Biolabs
From bench to breakthrough, Crux Biolabs - one of Australia’s leading clinical research organisations - helped Diag-Nose to deliver the analytics and proof-of-concept evidence that continues to power our studies.
From 2020 to 2022 our work through Crux spanned everything from core, foundational spike-and-recovery assessments, long-term sample storage and stability testing, to essential optimisation for ELISA and LUMINEX assays.
Working with complex biological samples is no small task - strict transport, regulatory and compliance requirements demand deep expertise.
Yet, given Crux Biolabs’ experience supporting companies like Noxopharm, PIOtx, and Imugene in advancing their missions, partnering with them was an easy choice.
Crux’s state-of-the-art PC2 laboratories accelerated our comprehensive biomarker testing, optimising the critical parameters that underpin nasal fluid handling and analysis. It goes without saying that Crux Biolabs expertise in sample transport was vital - simplifying Australian customs and logistics, accelerating access to expert analysis.
Challenge accepted: How do we handle nasal fluid?
As a biological sample, nasal fluid requires precision handling at every stage.
Working with nasal fluid at PC2 level is non-trivial.
Nasal fluid samples sit at the intersection of biological complexity, biosafety requirements, and analytical fragility. Without the right infrastructure, expertise, and controls, valuable signal is easily lost before analysis even begins.
Where Crux Biolabs come into play
Outsourcing our PC2-compliant laboratories promotes reliable processing and analysis of nasal fluid at scale, meeting biosafety, transport, and regulatory requirements without compromising data quality. Additionally pre-analytical variables can be systematically controlled and optimised.
We have evidence that purpose-built protocols for high-sensitivity immunoassays like ELISA and LUMINEX can be successfully adapted for nasal fluid. Not to mention that end-to-end sample handling workflows are now validated, from customs clearance and biospecimen receipt through to long-term storage and downstream analysis.
The outcome?
Our study confirms that distinct proteins can be detected in nasal fluid and that they correlate with disease activity and endotypes.
This collaboration establishes a credible, repeatable foundation for future studies and downstream translation. It turns nasal fluid from a “difficult sample” into a dependable analytical input, enabling the next phase of respiratory biomarker innovation.
This evidence lays a solid foundation for future research, strengthens the backbone of our company, and reinforces the importance of our mission.
These insights not only validate our approach but also open the door to new possibilities in respiratory disease diagnostics and patient care
Keep an eye out for our latest breakthrough and behind-the scenes updates by following us on LinkedIn!